TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Normalization of circulatory immune complexes (CIC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immediate verbal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Beck Depression Inventory (BDI) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with Life Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: multivitamin intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: felodipine area under the plasma drug concentration-time profile (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma peak drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent elimination half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum anti‐Müllerian hormone (AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: antral follicle count (AFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Muscle tone reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DAS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGA improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression severity measured by PHQ-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression severity measured by BDI-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ST-segment elevation in ECG leads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum beta-carotene concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery of sensory and motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodyweight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious adverse events requiring discontinuation of therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Mouthguard usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal-and-flare responses to antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cell counts of neutrophils, eosinophils, and T lymphocytes at antigen sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extracellular deposition of lactoferrin and ECP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pathological complete response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Breast-conserving surgery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improved functioning of the fronto-parietal region during loss anticipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SVR 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trough IC increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Compliance with protein substitute regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma phenylalanine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma tyrosine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Health distress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in average number of errors per screw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Systolic blood pressure postinduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic blood pressure postinduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rectal mucosal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: splenic flexure mucosal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: skin surface lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: xerosis improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incidence of acute renal rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in overall perception of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge about PCa treatment success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitudes about community‐based interventions for increasing awareness of PCa
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preventive prostate examination adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of daily pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distal sensory neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: All-cause mortality or hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in wart area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of mothers achieving a 50% increase in milk volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean axillary sweat production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDSS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early minor complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality due to biliary-related cause
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in PANSS negative subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SANS dimensions of affective flattening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SANS dimensions of alogia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of late effects (osteo‐ and soft tissue necrosis)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in number of UTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in bladder capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Favorable outcomes (VABS‐II ≥70)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reductions in perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increases in emotional and psychological well‐being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean BASDAI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of lesions resolving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sperm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: ejaculate quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Adjusted 1-year mortality
Endpoint domain: Mortality/survival
Primary endpoint: total syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemorheology index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL-C, LDL-C, and CETP activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of RTS,S/AS02D vaccine against first infection with P. falciparum malaria
Endpoint domain: Adverse events/effects
Primary endpoint: Seropositive titers for anticircumsporozoite antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to reach maximal plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean basal endogenous glucose production (EGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean maximum absolute S(EGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean maximum absolute increase in GU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: knowledge application
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HDL-cholesterol change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of CAP determination for specific IgE to celery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive predictive value of SPT and CAP tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: daily level of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of unsafe transportation in cargo area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upregulation of proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decline in LP (Late Toxicity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-radiation urethral strictures
Endpoint domain: Adverse events/effects
Primary endpoint: Extrapyramidal motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with severe asthma/poor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with optimal metered dose inhaler (MDI) technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with optimal dry powder inhaler (DPI) technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to pelvic floor exercises
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intrahepatic failure (IFC)
Endpoint domain: Mortality/survival
Primary endpoint: Central corneal thickness (CCT) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ureteric stone expulsion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inhibition of supragingival plaque development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of gingivitis development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe pain occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of repetition of the biopsy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perinatal morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: T3 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T3/T4 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TPOAb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TgAb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in dandruff
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: NIH-CPSI score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IPSS urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Degree of sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: verbal analog pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pitcher reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weeks of competitive employment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recall of fear extinction memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic stress reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress-induced negative affect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Rating Scale for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compressed soft tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D2/3 receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential expression of proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall cosmetic appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: static compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Confidence in assessment of runoff vessels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measured leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Preference for nasal mask
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: k(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elbow flexors muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: lean tissue mass (LTM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: bench press 1-RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: nausea and vomiting rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total body lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure freedom for more than 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of seizure frequency from baseline greater than 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soluble intracellular adhesion molecule‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: vascular cell adhesion molecule‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent change of concanavalin A‐induced proliferation of peripheral blood mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decreases of aspartate aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decreases of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete remission (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: incidence of symptomatic pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative signs of infection
Endpoint domain: Adverse events/effects
Primary endpoint: long-term effects of treatments for ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of penile rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral clearance of zolpidem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of zolpidem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free serum testosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Non-reassuring FHR tracings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to achieve maximum PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recovery of neurological and cognitive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: arithmetic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in auditory hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in general psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total days of non-birth-related infant hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodes of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repeat pregnancies in the first 2 years postbirth
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: complete response (no vomiting or rescue medication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum nausea (measured using a 100‐mm visual analog scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Watcha score incidence and frequency distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived maternal health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: healthier weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total health care charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: needle-stick pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedural pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal fat excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General well being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: median viral load at month 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal blood pressure dip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood total estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: bioavailable estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Functional Independence Measurement (FIM) motor and total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIM cognitive scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion using or intending to use FA supplements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T25FW responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss at 34 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight maintenance at 86 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in mean severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes